MedWatch

New US bio-terror law could spell good news for Bavarian Nordic

The Danish biotech company Bavarian Nordic sees it as good news that the US Congress has passed a law to maintain the US bio-terror alert system.

Foto: PR Bavarian

When the US Senate agreed to put aside 2.8 billion dollars to maintain the US bio-terror defence system recently, it did not just spell good news for American citizens, but also for Bavarian Nordic, the Danish company says in a press release.

"We are very pleased that the U.S. government has committed to maintaining and improving their stockpile of medical countermeasures by reauthorizing $2.8 billion in BioShield funding over the next five years," says Bavarian Nordic President and CEO Anders Hedegaard. "This new law will also speed up medical countermeasure development which will benefit our long-term relationship with the U.S. government on the development and stockpiling of current and future biodefense vaccines."

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Her er de vigtigste nyheder fra MedWatch i uge 39

Et konsortium står til at overtage Ferrosan Medical Devices, der kan være klar til en børsnotering inden for en femårig tidshorisont. Derudover fortsætter kampen om medarbejderne i branchen, mens Novo Nordisk har indgået en ny aftale. Gik du glip af noget?

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier